Daiichi Sankyo begins phase 3 trial of mutant strain Covid-19 vaccine, DS-5670 in Japan

Daiichi Sankyo announced that it has administered an mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (Covid-19), which is being developed by Daiichi Sankyo in Japan, to the first subject in a phase 3 clinical trial of a booster vaccination with an Omicron-adapted bivalent vaccine (booster vaccination trial). This booster vaccination trial is a phase 3 clinical trial that enrolls approximately 1,400 healthy individuals who have completed the primary and booster series of vaccination with a Covid-19 vaccine approved in Japan and evaluates the efficacy and safety of DS-5670 (Omicron-adapted bivalent vaccine) using a Covid19 vaccine (Omicron-adapted bivalent vaccine) approved in Japan as the control. Based on results from the booster vaccination trial, Daiichi Sankyo will pursue the approval of the Omicron adapted bivalent vaccine. Furthermore, the company will continuously work toward supplying mRNA vaccines against new variants of coronavirus. DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by Daiichi Sankyo. It is designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus and thus expected to have desirable prevention against Covid-19 and safety. Daiichi Sankyo aims to make it possible to distribute the mRNA vaccine at refrigeration temperatures (2-8?). The clinical development of DS-5670, including the mutant strain vaccine announced today, is being conducted through the

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!